Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Ca-A Cancer Journal for Clinicians | 2018 | 41.6K |
Cancer statistics, 2018 | Ca-A Cancer Journal for Clinicians | 2018 | 12K |
Ovarian cancer statistics, 2018 | Ca-A Cancer Journal for Clinicians | 2018 | 1.3K |
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 897 |
Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society | Ca-A Cancer Journal for Clinicians | 2018 | 759 |
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† | Annals of Oncology | 2018 | 645 |
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL | Blood | 2018 | 607 |
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States | Ca-A Cancer Journal for Clinicians | 2018 | 537 |
Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists | Annals of Oncology | 2018 | 529 |
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party | Blood | 2018 | 528 |
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer | International Journal of Clinical Oncology | 2018 | 503 |
The biology and role of CD44 in cancer progression: therapeutic implications | Journal of Hematology and Oncology | 2018 | 432 |
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia | Blood | 2018 | 382 |
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer | Annals of Oncology | 2018 | 376 |
Next generation of immune checkpoint therapy in cancer: new developments and challenges | Journal of Hematology and Oncology | 2018 | 375 |
MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile | Cytokine | 2018 | 372 |
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome | Blood | 2018 | 359 |
CTLA-4: a moving target in immunotherapy | Blood | 2018 | 356 |
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 355 |
The MLL recombinome of acute leukemias in 2017 | Leukemia | 2018 | 328 |
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity | Leukemia | 2018 | 323 |
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 316 |
Comprehensive analysis of the clinical immuno-oncology landscape | Annals of Oncology | 2018 | 311 |
Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening | Ca-A Cancer Journal for Clinicians | 2018 | 306 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Annals of Oncology | 2018 | 302 |